Obesity market overview. Market indicators

Nature Reviews Drug Discovery

Volumn 1, Issue 4, 2002, Pages 257-258

  Farrigan, Christine ^a   Pang, Kevin ^a  

^a Decision Resources Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; AMFEBUTAMONE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; ATL 962; AZ 40140; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID RECEPTOR ANTAGONIST; CARBOXYPEPTIDASE; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; GI 181771; HORMONE RECEPTOR BLOCKING AGENT; LY 377604; MELANIN CONCENTRATING HORMONE; MELANOCORTIN 4 RECEPTOR; MLN 4760; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; P 57; PEPTIDE HYDROLASE INHIBITOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT LEPTIN; RIMONABANT; SB 418790; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THYROID HORMONE RECEPTOR; TOPIRAMATE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC TRANSMISSION; CLINICAL TRIAL; COST OF ILLNESS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MORBIDITY; MORTALITY; OBESITY; OPTIMAL DRUG DOSE; PREVALENCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SUSTAINED DRUG RELEASE; ARTICLE; ECONOMICS;

ANTI-OBESITY AGENTS; HUMANS; OBESITY;

EID: 0242332276     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd781     Document Type: Review

References (0)